Semaglutide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Semaglutide — GLP-1R Selective Agonist

Semaglutide is a synthetic GLP-1 analog engineered for extended receptor activity through structural modifications that confer resistance to enzymatic degradation and reversible albumin binding — resulting in a significantly prolonged half-life compared to native GLP-1. As a selective GLP-1 receptor agonist, it mimics the actions of the endogenous incretin hormone GLP-1, making it one of the most extensively studied peptides in metabolic and glucose homeostasis research. Its well-characterized pharmacology and long-acting profile have made it a cornerstone reference compound across a wide range of research models.

Why Selective GLP-1R Agonism Matters

Unlike dual or triple agonists, semaglutide’s value in research lies in its receptor selectivity. Its clean GLP-1R binding profile allows researchers to isolate and characterize GLP-1-specific mechanisms without confounding signals from GIPR or GcgR pathways — making it an ideal comparator compound in studies involving multi-agonist peptides.

The CNS component is an emerging area of particular research interest — semaglutide’s ability to engage GLP-1 receptors in the brain’s reward circuitry has opened inquiry into appetite regulation beyond simple caloric signaling, as well as exploratory research into neuroprotective and addiction-related pathways.

Research Applications

Semaglutide is used in studies examining:

• Dose-response characterization of GLP-1R agonism across metabolic endpoints
• Body composition and adipose tissue changes under sustained receptor activation
• Comparative efficacy benchmarking against dual and triple agonist compounds
• Glucose and insulin dynamics in metabolic models
• Hepatic lipid accumulation and fatty liver (MASLD/MASH) pathways
• CNS reward pathway modulation and appetite-related neurological signaling
• Cardiovascular and renal risk factor research in metabolic disease models

Specifications

Reconstitution

Semaglutide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 5mg vial + 2mL BAC water = 2.5mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Due to semaglutide’s potency and long half-life (~160 hours), protocols typically employ a gradual titration schedule to allow characterization of receptor adaptation and observation of dose-dependent effects.

Typical titration framework:

• Starting dose: 0.25mg per administration
• Escalation: Increase by 0.25–0.5mg every 2–4 weeks as tolerated
• Frequency: Once weekly (consistent with its long half-life profile)
• Study duration: 8–16 weeks for body composition and metabolic endpoints

Commonly observed effects in research models:

• GI-related (receptor-mediated, typically transient): Nausea, vomiting, diarrhea, constipation, reduced appetite, early satiety, abdominal discomfort — most pronounced during dose escalation and generally self-limiting
• Metabolic: Reduced caloric intake, fluid balance shifts, electrolyte considerations at sustained higher doses
• Other: Injection site irritation, headache, mild dizziness at escalation intervals

Research Stacks

Semaglutide is commonly paired in research settings with:

• Tirzepatide — Tirzepatide adds GIP receptor co-agonism to GLP-1 receptor activity; researchers pair both to study the incremental metabolic effects of dual versus mono incretin receptor engagement, particularly in models of glucose homeostasis and appetite regulation.
• CJC-1295 No DAC / Ipamorelin — CJC-1295 No DAC and Ipamorelin stimulate the GH/IGF-1 axis via GHRH and ghrelin receptors; pairing with Semaglutide’s GLP-1 agonism allows researchers to examine interactions between incretin signaling and growth hormone secretagogue pathways in metabolic models.
• MOTS-c — MOTS-c activates AMPK to enhance mitochondrial efficiency and insulin sensitivity at the cellular level. Combining with Semaglutide provides a model to study peripheral insulin sensitization alongside GLP-1-mediated central and pancreatic signaling.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.